1. Baker is trying to sell the idea of quickly seeking approval of the rare cancer drug.
Baker is trying to hint that the drug has good results in the phase II trial so far. Enrollment is not complete. 41 of 58 was enrolled and needs to restart the trial process.
2. there will be uptick in cash burn
3. psma imaging agents are good portfolio to have
not sure how this plays with psma adc.
4. Baker says that it is a good deal since the acquired company was stuck
5. based on my impression, it seems the total outstanding share count is 50 million since 4.5 million is 9% of the total (anyone disagree?)
6. finally, Baker sounds like a sharp and confident guy with strong conviction of his judgment. Unlike the stupid Hobbs at DCTH.
1. Any idea how big the market (rev) is for the cancer drug? Progenics needs a revenue stream to keep the cash burn low. Assuming we don't have Relistor to count on, if we can't get reasonable income stream from the new drug in a short time frame, why do the deal.
Is it possible that PGNX wants to couple the Molecular Insight drug(s) with the anti-PMSA antibodies? Even if that were possible, it seems like a long way off from trials. We would have to be able to find out what the scoop is with the Molecular Insight drugs on their own to understand the rationale behind PGNX buying it.
should be very small market since it was said to be an ultra orphan drug.
Relistor does provide revenue even it is smaller than expenses. Off label prescription is there and FDA can't stop its off label use by doctors. After all, it is the only approved drug to counteract opioid directly. The fact that Relistor can't get expanded label prevents competitors entering the same market so I think the improved peak sale is very likely.